Sign In
New User?
Register for Mayo Medical Laboratories
MayoAccess™
Use
Manage
Contact Us
United States, Canada
- 800-533-1710
- 507-266-5700
- More options
International
- +1 507 266 5700
- More options
Quick Links
Reference Laboratory Services for
Health Care Organizations
Hot Topics
The Region 4 Stork (R4S) Collaborative Project, Part 3: Post-Analytical Interpretive Tools
Newborn screening has been very successful in identifying newborns with classic syndromes. However, many newborns have complex metabolic profiles that are difficult to interpret, leading to false-positives and missed diagnoses. To improve detection of true-positives, the Regional Genetics Collaborative project, funded by the Health Resource and Service Administration, has created the Region 4 Collaborative Stork project, which uses Mayo-developed software for postanalytical interpretation of complex metabolic profiles.
R4S Collaborative Project Part 3 explains how to use the post-analytical interpretive tools.
A 6-part presentation by Piero Rinaldo, MD, PhD
Published on June 17, 2013View presentation...
Leveraging the Laboratory: Advance Your Outreach Conference
Register Now!
Date: October 9-10, 2013
Location: Loews Atlanta Hotel in Atlanta, GA
This conference addresses the evolving needs of providers, and identifies the role of the laboratory, not only as a hidden revenue source, but also as a catalyst for further success.
Published on June 13, 2013 Learn more...
Hot Topics
HLA-B*5801 Testing for Allopurinol Severe Cutaneous Adverse Reactions
Allopurinol is a widely used treatment for hyperuricemia-related diseases, but the drug carries the risk of severe adverse cutaneous drug reactions including Stevens Johnson syndrome and toxic epidermal necrolysis, which are considered medical emergencies as they can result in fatalities. This hypersensitivity reaction to allopurinol has been linked to the HLA-B*5801 allele, which is present in both susceptible and healthy individuals at frequencies that vary by ethnicity. Pretreatment testing for HLA-B*5801, in either blood or saliva, can help identity those at risk for these complications.
A presentation by John Logan Black, MD
Published on June 10, 2013View presentation...
Hot Topics
The Region 4 Stork (R4S) Collaborative Project, Part 2: First Generation Productivity Tools
Newborn screening has been very successful in identifying newborns with classic syndromes. However, many newborns have complex metabolic profiles that are difficult to interpret, leading to false-positives and missed diagnoses. To improve detection of true-positives, the Regional Genetics Collaborative project, funded by the Health Resource and Service Administration, has created the Region 4 Collaborative Stork project, which uses Mayo-developed software for postanalytical interpretation of complex metabolic profiles.
Part 2 demonstrates the use of first generation productivity tools.
A 6-part presentation by Piero Rinaldo, MD, PhD
Published on June 3, 2013View presentation...
Coagulation Disorder Testing
Comprehensive Testing for:
- Thrombophilia
- Hemophilia
- Lupus Anticoagulant
- von Willebrand's Disease
- Prolonged Clotting Time
- Disseminated Intravascular Coagulation
- Platelet Disorders
- Thrombotic Microangiopathy (TMA)
Published on May 30, 2013 Learn More...
15th Bleeding and Thrombosing Diseases Conference
Register Now!
Date: August 7-9, 2013
Location: The Kahler Grand Hotel in Rochester, MN
Focusing on the laboratory and clinical aspects of bleeding and thrombosing disorders, this conference will cover:
- The basics of hemostasis
- Platelet disorders and von Willebrand Disease
- Plasmatic coagulopathies
- A variety of hemostasis and thrombosis topics
Published on May 23, 2013 Learn more...
Now Performed at Mayo Medical Laboratories
Nuclear Magnetic Resonance (NMR) Lipoprotein Particle Testing Using LipoScience Vantera Clinical Analyzer
Mayo Medical Laboratories is now performing NMR lipoprotein particle testing using the Vantera Analyzer, which identifies and quantifies concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms.
This analysis provides physicians and patients with a detailed assessment of cardiovascular disease risk from a single blood test that measures the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information.
Published on May 22, 2013 View test...
View press release and additional information...





